疾病自然疗法

分享&收藏

按拼音首字母检索:

« 返回疾病自然疗法导航

医博士-疾病自诊工具

选择症状,点点鼠标,便可查找病因。

开始自诊

间歇性跛行自然疗法

当动脉粥样硬化到了进展期时,可能会严重堵塞供应双下肢血液的动脉。这时,病人可能在行走了一小段距离之后就会感到下肢严重的痉挛性疼痛,这种状态就称为间歇性跛行 (Intermittent claudication)。间歇性跛行的严重程度通常是根据患者无痛性行走的距离来衡量的。

间歇性跛行

间歇性跛行的常规治疗包括服用控制动脉粥样硬化的药物、巡能泰 (Trental) 或者己酮可可碱 (Pentoxifylline) 及其它药物。情况严重时,可能需要做手术来改善下肢血运。另外,有许多天然疗法对间歇性跛行可能有益,但是不清楚和药物同时服用是否安全。由于该疾病比较严重,需要留心病情的变化。

  • 银杏 (Ginkgo):很多研究支持银杏治疗间歇性跛行的有效性。根据9项双盲临床试验,银杏能显著增加无痛性行走距离,这很可能与它增加血液循环的功能有关。例如,一项研究,有111例患者参与,随访了2年。评估指标是患者无痛性行走距离。试验开始时两组 (银杏组和安慰剂组) 参与者无痛性行走均只有120米。而在试验结束时,银杏组比安慰剂组改善明显,行走距离约增加40%。增大服用剂量效果可能会更好。一项为期24周涉及74例患者的双盲研究发现每天服用银杏240mg要比每天120mg更有效。
  • 银杏

  • L-卡尼汀 (L-Carnitine):它是一种类似于维生素的一种物质,同样显示出对治疗间歇性跛行有疗效。虽然它不能增加血流,但可能是通过改善肌肉对能量的利用来增加行走距离。一项为期12个月485位患者参与的双盲研究评估了L-卡尼汀的疗效。与安慰剂组相比,病情较重的患者无痛性行走距离增加了44%。但是病情较轻的患者改善不明显。其他几项研究也证实了L-卡尼汀对严重间歇性跛行的疗效。
  • 肌醇烟酸酯 (Inositol Hexaniacinate):肌醇烟酸酯是一种特殊的维生素B3,它对间歇性跛行也有一定的疗效。一项有400例患者参与的双盲研究发现它能改善患者无痛性行走距离。另外,在一项有100例患者参与的试验中每天给予参与者安慰剂或4g肌醇烟酸酯。经过3个月治疗,服用肌醇烟酸酯的参与者明显改善了无痛性行走距离。
  • 间质聚糖 (Mesoglycan):它是一种在体内许多组织中都存在的物质,包括关节、肠道、血管内皮等。一项为期20周的双盲研究评估了间质聚糖对242例间歇性跛行患者的治疗效果。结果显示服用间质聚糖的参与者治疗反应良好,比安慰剂组相比,有更多的人其行走距离增加了50%。
参考文献
  1. Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med. 2000;108:276-281.
  2. Peters H, Kieser M, Holscher U. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication—a placebo-controlled, double-blind multicenter trial. Vasa. 1998;27:106-110.
  3. Blume J, Kieser M, Holscher U. Placebo-controlled, double-blind study on the effectiveness of ginkgo biloba special extract EGb 761 in trained patients with intermittent claudication [translated from German]. Vasa. 1996;25:265-274.
  4. Schweizer J, Hatmann C. Comparison of two dosages of Ginkgo biloba extract EGb 761 in patients with peripheral arterial occlusive disease Fontaine's Stage IIb. A randomized, double-blind, multicentric clinical trial. Arzneimittelforschung. 1999;49:900-904.
  5. Sabba C, Berardi E, Antonica G, et al. Comparison between the effect of L-propionylcarnitine, L-acetylcarnitine and nitroglycerin in chronic peripheral arterial disease: a haemodynamic double blind echo-Doppler study. Eur Heart J. 1994;15:1348-1352.
  6. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol. 1999;34:1618-1624.
  7. Brevetti G, Perna S, Sabba C, et al. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol. 1995;26:1411-1416.
  8. Bolognesi M, Amodio P, Merkel C, et al. Effect of 8-day therapy with propionyl-L-carnitine on muscular and subcutaneous blood flow of the lower limbs in patients with peripheral arterial disease. Clin Physiol. 1995;15:417-423.
  9. Brevetti G, Perna S, Sabba C, et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J. 1992;13:251-255.
  10. Greco AV, Mingrone G, Bianchi M, et al. Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double blind trial versus placebo. Drugs Exp Clin Res. 1992;18:69-80.
  11. Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation. 1988;77:767-773.
  12. Deckert J. Propionyl-L-carnitine for intermittent claudication. J Fam Pract. 1997;44:533-534.
  13. Sabba C, Berardi E, Antonica G, et al. Comparison between the effect of L-propionylcarnitine, L-acetylcarnitine and nitroglycerin in chronic peripheral arterial disease: a haemodynamic double blind echo-Doppler study. Eur Heart J. 1994;15:1348-1352.
  14. Pepine CJ. The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther. 1991;13:2-21.
  15. Brevetti G, Attisano T, Perna S, et al. Effect of L-carnitine on the reactive hyperemia in patients affected by peripheral vascular disease: a double-blind, crossover study. Angiology. 1989;40:857-862.
  16. Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med. 2001;110:616-622.
  17. O'Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial. Br J Clin Pract. 1988;42:377-383.
  18. Kiff RS, Quick CR. Does inositol nicotinate (Hexopal) influence intermittent claudication? A controlled trial. Br J Clin Pract. 1988;42:141-145.
  19. Head A. Treatment of intermittent claudication with inositol nicotinate. Practitioner. 1986;230:49-54.
  20. Tyson VCH. Treatment of intermittent claudication. Practitioner. 1979;223:121-126.
  21. O'Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial. Br J Clin Pract. 1988;42:377-383.
  22. Nenci GG, Gresele P, Ferrari G, et al. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study. Thromb Haemost. 2001;86:1181-1187.
  23. Horsch S, Walther C. Ginkgo biloba special extract EGb 761 in the treatment of peripheral arterial occlusive disease (PAOD)—a review based on randomized, controlled studies. Int J Clin Pharmacol Ther. 2004;42:63-72.

最后修改日期 : 2009-03-23

© 2012 以上资料由医博士(DrMed)编辑。版权归医博士(DrMed) 和
新世纪医学公司(New Century Medicine,Inc.)所有,未经书面许可,不得转载!